Nuevolution, CRT Partner in Cancer Compound Hunt | GenomeWeb

NEW YORK (GenomeWeb News) – The Danish drug discovery firm Nuevolution said today that it will collaborate with Cancer Research Technology, the commercial branch of Cancer Research UK, to identify possible drug candidates for use in cancer treatments.

Under the collaboration, Nuevolution will use its Chemetics technology, which uses DNA labeling for small-molecule drug screening, to identify drug leads that block the activity of a number of cancer targets, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.